Vasopressin receptor antagonism - a therapeutic option in heart failure and hypertension

被引:32
|
作者
Burrell, LM [1 ]
Risvanis, J [1 ]
Johnston, CI [1 ]
Naitoh, M [1 ]
Balding, LC [1 ]
机构
[1] Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, Heidelberg, Vic, Australia
关键词
D O I
10.1111/j.1469-445X.2000.tb00031.x
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The precise role of vasopressin in the pathophysiology of cardiovascular disease is controversial, but this peptide hormone is important for several reasons. Firstly, circulating concentrations of vasopressin are elevated in heart failure and some forms of hypertension. Secondly, there is evidence that vasopressin is synthesized not only in the hypophysial-pituitary axis but also in peripheral tissues including the heart where it acts as a paracrine hormone. Thirdly, vasopressin has vasoconstrictor, mitogenic, hyperplastic and renal fluid retaining properties which, by analogy with angiotensin II, may have deleterious effects when present in chronic excess. Finally, the availability of orally active non-peptide vasopressin receptor antagonists allows vasopressin receptor antagonism to be considered as a therapeutic option in cardiovascular disease.
引用
收藏
页码:259S / 265S
页数:7
相关论文
共 50 条
  • [1] Vasopressin antagonism: a future treatment option in heart failure
    Sanghi, P
    Uretsky, BF
    Schwarz, ER
    EUROPEAN HEART JOURNAL, 2005, 26 (06) : 538 - 543
  • [2] Vasopressin antagonism in heart failure
    Goldsmith, SR
    Gheorghiade, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (10) : 1785 - 1791
  • [3] Is vasopressin-receptor antagonism an advancement in the treatment of heart failure?
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (10) : 2181 - 2184
  • [4] Vasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?
    De Vecchis, Renato
    Cantatrione, Claudio
    Mazzei, Damiana
    Baldi, Cesare
    JOURNAL OF CLINICAL MEDICINE, 2016, 5 (10)
  • [5] Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure
    Izumi, Yasukatsu
    Miura, Katsuyuki
    Iwao, Hiroshi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 (01) : 1 - 6
  • [6] The therapeutic potential of vasopressin receptor antagonists in congestive heart failure
    Salam, AM
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (05) : 687 - 691
  • [7] VASOPRESSIN ANTAGONISM IN CONGESTIVE-HEART-FAILURE
    STONE, CK
    SAKAMOTO, S
    LIANG, CS
    IMAI, N
    SLADEK, CD
    HOOD, WB
    CIRCULATION, 1987, 76 (04) : 208 - 208
  • [8] Hyponatremia and vasopressin antagonism in congestive heart failure
    Kumar, Siva
    Rubin, Sharon
    Mather, Paul J.
    Whellan, David J.
    CLINICAL CARDIOLOGY, 2007, 30 (11) : 546 - 551
  • [9] Vasopressin and Vasopressin Receptor Antagonists in Heart Failure
    Oghlakian, Gerard
    Klapholz, Marc
    CARDIOLOGY IN REVIEW, 2009, 17 (01) : 10 - 15
  • [10] Aldosterone receptor antagonism in heart failure
    Jennings, DL
    Kalus, JS
    O'Dell, KM
    PHARMACOTHERAPY, 2005, 25 (08): : 1126 - 1133